Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen omalizumab versus Xolair in uncontrolled moderate to severe allergic asthma
IRCT20150303021315N20Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in allergic asthma and asthma (2 arms), sponsored by CinnaGen. Primary endpoint: Rate of asthma exacerbations. Started Nov 2020; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on IRCT20150303021315N20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N20.